Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Pioglitazone

Gauri Singh  1 , Ahmet S. Can  2 , Ricardo Correa  3
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Book

Pioglitazone

Gauri Singh et al.

Excerpt

Pioglitazone is a drug used in the management of type 2 diabetes mellitus. Pioglitazone is the third marketed thiazolidinedione group of oral antidiabetics, the first is troglitazone which is no longer available due to hepatotoxicity, and the second is rosiglitazone, still on the market. This activity reviews the indications, mechanism of action, and contraindications for pioglitazone in managing type 2 diabetes mellitus. This activity highlights the mechanism of action, adverse effect profile, monitoring, and relevant interactions.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Gauri Singh declares no relevant financial relationships with ineligible companies.

Disclosure: Ahmet Can declares no relevant financial relationships with ineligible companies.

Disclosure: Ricardo Correa declares no relevant financial relationships with ineligible companies.

References

    1. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021 Jan;44(Suppl 1):S73-S84. - PubMed
    1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457-71. - PubMed
    1. Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jiménez F, Hardin PA, Konkoy CS, Tan MH. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther. 2003 Apr;25(4):1074-95. - PubMed
    1. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev. 2002 Mar-Apr;18 Suppl 2:S10-5. - PubMed
    1. El-Fayoumi S, Mansour R, Mahmoud A, Fahmy A, Ibrahim I. Pioglitazone Enhances β-Arrestin2 Signaling and Ameliorates Insulin Resistance in Classical Insulin Target Tissues. Pharmacology. 2021;106(7-8):409-417. - PubMed

Publication types